In first‑line oncology, enrollment stalls when investigator confidence lags. This global Phase 3 trial shows how momentum is engineered.
Case Study: Scaling a First Line NSCLC Trial in a Hesitant Market
Lisa Lopez
In first‑line oncology, enrollment stalls when investigator confidence lags. This global Phase 3 trial shows how momentum is engineered.